Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 4/20 | 0.40 |
| ▸ | CTSD | P07339 | 4/20 | 0.39 |
| ▸ | BACE1 | P56817 | 4/20 | 0.39 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | LIPC | P11150 | 1/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3645627 | 0.84 | CTSD (0.38) | DHODHCTSDBACE1BACE2GSK3B | |
| SCHEMBL3645629 | 0.82 | DHODH (0.36) | DHODHCTSDBACE1BACE2GSK3B | |
| SCHEMBL4131558 | 0.78 | AR (0.36) | DHODHNAPRTFFAR4ALDH1A1LMNA | |
| SCHEMBL4135851 | 0.78 | GSK3B (0.39) | DHODHCTSDBACE1BACE2GSK3B | |
| SCHEMBL4124015 | 0.77 | GRM1 (0.40) | DHODHNAPRTALDH1A1MAPT | |
| SCHEMBL4130796 | 0.76 | MGAM (0.36) | DHODHDYRK1ANAPRTAR | |
| SCHEMBL3645628 | 0.75 | DYRK1A (0.40) | DHODHCTSDBACE1BACE2GSK3B | |
| SCHEMBL4119122 | 0.74 | AR (0.33) | DHODHGSK3BDYRK1ANAPRTFFAR4 | |
| SCHEMBL3799051 | 0.74 | ALDH1A1 (0.35) | DHODHDYRK1AALDH1A1AR | |
| SCHEMBL4131192 | 0.73 | CTSD (0.34) | CTSDBACE1BACE2DYRK1AAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | DHODH 1560/4885CTSD 264/4885BACE1 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.